MedWatch

Novo Ventures invests millions in Bavarian Nordic rival

London-based biotech company Reviral has raised USD 55 million for the continued development of its phase II candidate against the respiratory disease RSV. Novo Ventures is among the investors.

Photo: Novo Holdings/PR

The competition is intensifying on the potential billion-dollar market for treatment of the respiratory disease RSV and now, Novo Holdings also sets the ball rolling.

Novo Ventures has invested an unknown sum in British Reviral in a series B fundraising that brought in USD 55 million for the company.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Latest news

See all jobs